Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25954086 | 0.89 | LTA4H (0.50) | PYCR1LMNAHTTNPSR1AOC3 | |
| SCHEMBL25954061 | 0.88 | ELANE (0.46) | LMNAAOC3ELANEALDH1A1MAPT | |
| SCHEMBL164160 | 0.88 | ELANE (0.46) | LMNAAOC3ELANEALDH1A1MAPT | |
| SCHEMBL10106949 | 0.83 | LTA4H (0.62) | LMNAHTTMEN1KMT2ANPC1 | |
| SCHEMBL25954058 | 0.83 | LTA4H (0.48) | LMNAHTTAOC3ELANEMEN1 | |
| SCHEMBL25954108 | 0.83 | LTA4H (0.48) | LMNAHTTAOC3ELANEMEN1 | |
| SCHEMBL25954105 | 0.83 | ESR2 (0.48) | AOC3ELANENPC1RAB9AALDH1A1 | |
| SCHEMBL25954134 | 0.83 | ELANE (0.42) | LMNAAOC3ELANEMEN1KMT2A | |
| SCHEMBL15947078 | 0.82 | LMNA (0.42) | LMNAHTTMEN1KMT2AL3MBTL1 | |
| SCHEMBL15947062 | 0.81 | KMT2A (0.36) | PYCR1LMNAHTTNPSR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916071-B2 | Chromene compound and curable composition | TOKUYAMA CORPORATION (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20140225050-A1 | CHROMENE COMPOUND AND CURABLE COMPOSITION | TOKUYAMA CORPORATION (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8778236-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8709308-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2014-04-29 | — | — | US | disclosed |
| US-8691120-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20140054520-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140034884-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2014-02-06 | — | — | US | disclosed |
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120270071-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120170098-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120161089-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | CRY2, CYP2J2, NR0B2 | PYCR1 162/4885LMNA 2468/4885HTT 2949/4885 |
| US-20120170098-A1 | CHROMENE COMPOUND | CRY2, CRY1, SUN2 | PYCR1 226/4885LMNA 755/4885HTT 1764/4885 |
| US-20120270071-A1 | CHROMENE COMPOUND | NR0B2, NR2C2, NR0B1 | PYCR1 163/4885LMNA 1095/4885HTT 3829/4885 |
| US-20140225050-A1 | CHROMENE COMPOUND AND CURABLE COMPOSITION | CRY2, CRY1, CDYL | PYCR1 773/4885LMNA 1960/4885HTT 1210/4885 |
| US-20120161089-A1 | CHROMENE COMPOUND | CYP8B1, HSD3B2, CYP17A1 | PYCR1 125/4885LMNA 1789/4885HTT 3687/4885 |
| US-20120121934-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | PYCR1 338/4885LMNA 3223/4885HTT 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.